Insulin oral - Oshadi Drug Administration
Alternative Names: Oshadi IcpLatest Information Update: 21 Jan 2022
Price :
$50 *
At a glance
- Originator Oshadi Drug Administration
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 25 Sep 2019 No development reported - Phase-II for Type 1 diabetes mellitus in Israel (PO)
- 01 Feb 2017 Oshadi Drug Administration completes a phase II trial for Type-1 diabetes mellitus in Israel (PO) (NCT01973920)
- 16 Feb 2016 Phase-II development is still ongoing in Israel (NCT01973920)